ARTICLE | Clinical News
CTL102/CB1954: Began Phase I/II trial
June 26, 2000 7:00 AM UTC
ML Laboratories plc (LSE:MLB), Liverpool, U.K. Product: CTL102/CB1954 Business: Gene/Cell therapy, Cancer Therapeutic category: Gene therapy Target: Cancer cells Description: Intratumoral injection of...